ZMYND8 and triple-negative breast carcinoma: In triple-negative breast cancer, TROJAN interacts with metastasis-repressing factor ZMYND8, subsequently increasing ZMYND8 degradation via the ubiquitin-proteasome pathway by repelling ZNF592, and thus enhancing cancer progression [6].